Comparative Activity and Specificity of Antisense Oligodeoxynucleotides and Small Interfering RNA in an in vitro Ewing Sarcoma Model

No abstract is available for this paper.

• Publication year

  2009

• Venue

  The Open Nanomedicine Journal

• Publication date

  2009-11-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/1875933500902010036
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• siRNA specificity searching incorporating mismatch tolerance data

  2008cited by this paper
• SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.

  2007cited by this paper
• Comparison of siRNA-induced off-target RNA and protein effects.

  2007cited by this paper
• Efficacy of siRNA Nanocapsules Targeted Against the EWS–Fli1 Oncogene in Ewing Sarcoma

  2006cited by this paper
• Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

  2006cited by this paper
• 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets

  2006cited by this paper
• The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors.

  2006cited by this paper
• Chemical modification of gene silencing oligonucleotides for drug discovery and development.

  2005cited by this paper
• Molecular therapeutics--lessons from the role of Src in cellular signalling.

  2005cited by this paper
• Oncogene-targeted antisense oligonucleotides for the treatment of Ewing sarcoma

  2005cited by this paper
• Ewing Sarcoma Family of Tumors

  2005cited by this paper
• The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells.

  2005cited by this paper
• Inhibition of Platelet-derived Growth Factor-induced Cell Growth Signaling by a Short Interfering RNA for EWS-Fli1 via Down-regulation of Phospholipase D2 in Ewing Sarcoma Cells*

  2005cited by this paper
• Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.

  2005cited by this paper
• EWS-ETS oncoproteins: the linchpins of Ewing tumors.

  2005cited by this paper
• 2'-O-methyl-modified phosphorothioate antisense oligonucleotides have reduced non-specific effects in vitro.

  2004cited by this paper
• Kinetic analysis of the RNAi enzyme complex

  2004cited by this paper
• Src family kinases, key regulators of signal transduction

  2004cited by this paper
• Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs).

  2004cited by this paper
• Design and applications of modified oligonucleotides.

  2003cited by this paper
• Oligonucleotides Targeted Against a Junction Oncogene Are Made Efficient by Nanotechnologies

  2003cited by this paper
• Cooperative Interaction of EWS with CREB-binding Protein Selectively Activates Hepatocyte Nuclear Factor 4-mediated Transcription*

  2003cited by this paper
• Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein

  2003cited by this paper
• Src family kinases in tumor progression and metastasis

  2003cited by this paper
• Expression profiling reveals off-target gene regulation by RNAi

  2003cited by this paper
• Therapeutic Potentialities of EWS‐Fli‐1 mRNA‐Targeted Vectorized Antisense Oligonucleotides

  2003cited by this paper
• Small RNAs with Imperfect Match to Endogenous mRNA Repress Translation

  2003cited by this paper
• Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line.

  2003cited by this paper
• Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.

  2002cited by this paper
• The EWS protein is dispensable for Ewing tumor growth.

  2001cited by this paper
• DNA Binding Domain-independent Pathways Are Involved in EWS/FLI1-mediated Oncogenesis*

  2001cited by this paper
• Cytoskeletal changes in cell transformation and tumorigenesis.

  2001cited by this paper
• Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G 1 regulatory genes

  2001cited by this paper
• EWS fli-1 antisense nanocapsules inhibits ewing sarcoma-related tumor in mice.

  2000cited by this paper
• Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity

  1999cited by this paper
• EWS, but Not EWS-FLI-1, Is Associated with Both TFIID and RNA Polymerase II: Interactions between Two Members of the TET Family, EWS and hTAFII68, and Subunits of TFIID and RNA Polymerase II Complexes

  1998cited by this paper
• EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.

  1997cited by this paper
• EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro.

  1996cited by this paper
• Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts.

  1995cited by this paper
• The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1

  1993cited by this paper
• Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation.

  1993cited by this paper
• 2'-O-alkyl oligoribonucleotides as antisense probes.

  1990cited by this paper
• In Vivo Potentialities of Ews-fli-1 Targeted Antisense Oligonucleotides-nanospheres Complexes

  year unknowncited by this paper

• Vers une thérapeutique ciblée du sarcome d’Ewing par une stratégie antisens

  2009cites this paper